Nothing Special   »   [go: up one dir, main page]

WO2003092632A3 - Agents anticancereux de peptides cycliques et leurs procedes d'utilisation - Google Patents

Agents anticancereux de peptides cycliques et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2003092632A3
WO2003092632A3 PCT/US2003/014373 US0314373W WO03092632A3 WO 2003092632 A3 WO2003092632 A3 WO 2003092632A3 US 0314373 W US0314373 W US 0314373W WO 03092632 A3 WO03092632 A3 WO 03092632A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer agents
methods
cyclic peptide
peptide anti
present
Prior art date
Application number
PCT/US2003/014373
Other languages
English (en)
Other versions
WO2003092632A2 (fr
Inventor
M Reza Ghadiri
Original Assignee
Scripps Research Inst
M Reza Ghadiri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, M Reza Ghadiri filed Critical Scripps Research Inst
Priority to AU2003232077A priority Critical patent/AU2003232077A1/en
Publication of WO2003092632A2 publication Critical patent/WO2003092632A2/fr
Publication of WO2003092632A3 publication Critical patent/WO2003092632A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à de nouveaux types d'agents anticancéreux et à leur procédés d'utilisation.
PCT/US2003/014373 2002-05-06 2003-05-06 Agents anticancereux de peptides cycliques et leurs procedes d'utilisation WO2003092632A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003232077A AU2003232077A1 (en) 2002-05-06 2003-05-06 Cyclic peptide anti-cancer agents and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37839502P 2002-05-06 2002-05-06
US60/378,395 2002-05-06

Publications (2)

Publication Number Publication Date
WO2003092632A2 WO2003092632A2 (fr) 2003-11-13
WO2003092632A3 true WO2003092632A3 (fr) 2007-11-01

Family

ID=29401603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/014373 WO2003092632A2 (fr) 2002-05-06 2003-05-06 Agents anticancereux de peptides cycliques et leurs procedes d'utilisation

Country Status (2)

Country Link
AU (1) AU2003232077A1 (fr)
WO (1) WO2003092632A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085777A2 (fr) 2000-05-09 2001-11-15 Greenville Hospital System Peptides therapeutiques formant des pores
US7456146B2 (en) * 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs
WO2010051667A1 (fr) * 2008-11-10 2010-05-14 复旦大学 Compositions pharmaceutiques comprenant des nanotubes de peptide cyclique et utilisations de celles-ci
ES2342874B2 (es) * 2010-02-19 2011-01-27 Fundacio Privada Institut D'investigacio Biomedica De Girona Dr. Josep Trueta Peptidos ciclicos inhibidores del crecimiento celular.
WO2013025099A1 (fr) * 2011-08-17 2013-02-21 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Substrats pour la détection de périopathogènes de la cavité buccale
CN104583229B (zh) * 2012-08-29 2020-06-16 新加坡科技研究局 肽及其应用
CA2908552A1 (fr) * 2013-04-02 2014-10-09 The Scripps Research Institute Utilisations de peptides cycliques pour traiter et prevenir l'atherosclerose
DK3149025T3 (da) 2014-05-21 2019-07-22 Entrada Therapeutics Inc Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
EP3185880B1 (fr) 2014-08-27 2020-02-12 Ohio State Innovation Foundation Inhibiteurs améliorés de la peptidyl-calcineurine
WO2016115140A1 (fr) * 2015-01-13 2016-07-21 Boston Scientific Scimed, Inc. Dépolarisation de membranes de cellules cancéreuses
CN106699841B (zh) * 2017-01-05 2020-07-24 北京大学深圳研究生院 一种自组装的多肽纳米棒及其制备方法
EP3749365A4 (fr) 2018-01-29 2022-01-12 Ohio State Innovation Foundation Inhibiteurs peptidyliques de l'interaction calcineurine-nfat
CA3092062A1 (fr) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions et methodes de traitement de l'encephalopathie mitochondriale neurogastro-intestinale
WO2019217682A1 (fr) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Peptides cycliques de pénétration cellulaire avec un ou plusieurs résidus hydrophobes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6277818B1 (en) * 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor

Also Published As

Publication number Publication date
AU2003232077A8 (en) 2003-11-17
WO2003092632A2 (fr) 2003-11-13
AU2003232077A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
AU2003247798A1 (en) Nozzles and components thereof and methods for making the same
WO2004058159A3 (fr) Composes immunomodulateurs ramifies et leur procedes d'utilisation
EP1660638A4 (fr) Lipoparticules comprenant des proteines, et procedes de production et d'utilisation de ces lipoparticules
IL212752A0 (en) An molecule directed against the ??-secretase cleavage site of amyloid precursor protein, and uses thereof
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
IL171109A (en) Glycopagilization methods and proteins / peptides produced by these methods
WO2003077867A3 (fr) Compositions a base de chlorhydrate de naltrexone
AU2003212458A1 (en) Cyclo(n)pyrroles and methods thereto
WO2003103571A3 (fr) Vaccins contre les flavivirus
WO2003092632A3 (fr) Agents anticancereux de peptides cycliques et leurs procedes d'utilisation
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
WO2004009616A3 (fr) Analogues de la ghreline
AU2003295843A8 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
WO2004052312A3 (fr) Agents anti-infectieux
WO2003031585A3 (fr) Molecules d'acide nucleique codant une serine protease transmembranaire 25, polypeptides codes et procedes connexes
WO2003092631A3 (fr) Agents antiviraux de peptides cycliques et leurs procedes d'utilisation
WO2005087932A3 (fr) Vecteurs pour le clonage directionnel
AU2003206367A1 (en) Technical field of the invention
WO2004050613A3 (fr) Derives de 3-propenamide substitue en 2 et procedes d'utilisation de ces derives
WO2004016640A3 (fr) Intermediaires de 5 androstene-3?-ol steroides et leurs procedes de preparation
WO2004019965A3 (fr) Approches tolerogenes a base de thymus destinees au diabete de type i.
WO2004047751A3 (fr) Composes calcilytiques
EP1517879A4 (fr) Aminoalkylphenols et leurs procedes d'utilisation et de fabrication
AU2002330245A1 (en) Isolated polypeptides and compositions from the venom of p. transvaalicus and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP